Formycon AGFRA:FYB 65 OCF Yield % is 3.23 as of Jul. 04, 2026. GuruFocus rates FRA:FYB with a GF Score™ of 65/100 and a GF Value™ of €35.55 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,414 Biotechnology companies, Formycon AG ranks better than 86.85% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Formycon AG OCF Yield % Related Terms
Formycon AG OCF Yield % Historical Data
* Premium members only.
The historical data trend for Formycon AG's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:FYB vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Formycon AG's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formycon AG OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formycon AG's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Formycon AG's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formycon AG (FRA:FYB) has a OCF Yield % of 3.23 as of Jul. 04, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Formycon AG and its competitors. According to the industry distribution chart, Formycon AG ranks #186 out of 1414 companies in the Biotechnology industry, placing it in the top 13.2%.
Is Formycon AG's OCF Yield % too high?
Formycon AG's current OCF Yield % is 3.23. Based on the distribution chart, Formycon AG ranks #186 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Formycon AG has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #186 out of 1414 companies for OCF Yield %. This places Formycon AG in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Formycon AG and its competitors. Formycon AG's current OCF Yield % is 3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Based on GuruFocus' analysis, Formycon AG (FRA:FYB) is currently considered Possible Value Trap. The stock's GF Value™ is €35.55, compared to a current price of €19.12 — trading 46.2% below its estimated fair value. The current OCF Yield % is 3.23. Formycon AG's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Formycon AG (FRA:FYB), the current OCF Yield % is 3.23 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formycon AG (FRA:FYB) Overvalued in 2026?
Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued.
The current stock price of €19.12 is trading 46.2% below its estimated GF Value™ of €35.55.
GuruFocus considers Formycon AG to be Possible Value Trap.
Key valuation signals for FRA:FYB:
OCF Yield %: 3.23
GF Value™: €35.55 vs. price of €19.12 (46.2% below fair value)
No single metric tells the full story. See the FRA:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
65GF Score
Get the complete analysis for FRA:FYB
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FYB has been successfully added to your 
